此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估鲍曼尼杆菌杆菌患者中磺胺乳酰胺甲酰胺的研究

2026年10月2日 更新者:Innoviva Specialty Therapeutics

一项多中心,开放标签的1B研究,用于评估住院儿科患者在住院的儿科患者中的药代动力学,安全性和耐受性

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

研究概览

研究类型

介入性

注册 (估计的)

48

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Los Angeles、California、美国、90095
        • 招聘中
        • UCLA Medical Center
      • San Diego、California、美国、92123
        • 招聘中
        • Rady Children's Hospital
    • North Carolina
      • Greenville、North Carolina、美国、27834
        • 招聘中
        • ECU Brody School of Medicine
    • Texas
      • Galveston、Texas、美国、77555-5302
        • 招聘中
        • University of Texas Medical Branch at Galveston

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1天 至 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patient from birth (defined as post-natal age of 7 days) to <18 years of age at the time of written informed consent (and assent, if applicable) and is hospitalized.
  2. Patient and/or parent(s) or legal guardian(s) have provided the written informed consent and/or assent.
  3. Patient has confirmed or suspected diagnosis of ABC infection and requires IV antibiotics for treatment.
  4. Patient has expected survival of 30 days after enrollment in the study.
  5. If patient is an individual of childbearing potential or reproductive potential, then the patient must remain abstinent OR must utilize one of the highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, or injectable) from at least 30 days prior to screening until at least 30 days after administration of the last dose of study drug.

Exclusion Criteria:

  1. Patient is a preterm infant, born at <28 weeks gestational age.

  2. Patient has history of significant hypersensitivity or allergic reaction to any β-lactam, any contraindication to the excipients used in the formulation, or any contraindication to the use of β-lactam antibiotics. Note: For β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment.

  3. Patient is in refractory septic shock at the time of enrollment, defined as persistent hypotension despite adequate fluid resuscitation or vasopressive therapy.

  4. Patient is pregnant, breastfeeding, or intends to become pregnant.

  5. Patient is receiving peritoneal dialysis or cardiopulmonary bypass.

  6. Patient has received blood transfusion within 24 hours of study drug administration.

  7. Patient is a newborn with clinically significant anemia who, in the opinion of the investigator, will not be able to tolerate the necessary blood draws to complete the study activities.

  8. Patient (or patient's mother, if the patient is being breastfed) is using or will need to use any medications known to inhibit organic anion transporter 1 (OAT1) (eg, probenecid).

  9. Patient has clinically significant renal, hepatic, or hemodynamic instability.

  10. For Cohorts 1 through 3 only: patient has weight outside of the 5th to 95th percentile based on age.

  11. Patient has an age-appropriate estimated creatinine clearance that indicates renal impairment.

  12. Patient has the following laboratory results at Screening:

    1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×upper limit of normal (ULN) and,
    2. Total bilirubin >2×ULN for age with conjugated/direct bilirubin >20% of the total. Note: Patients with AST or ALT up to 5×ULN are eligible if these elevations are acute and are documented as being directly related to the infectious process being treated.
  13. Patient has clinically significant abnormal laboratory test results not related to the underlying infection that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial.

  14. Patient (or patient's mother, if the patient is being breastfed) has participated in a clinical study involving investigational medication or an investigational device within the last 30 days or 5 half-lives, whichever is longer, prior to first dose of the study drug.

  15. Patient has any condition that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data.

  16. Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.

  17. Patient (or patient's mother, if the patient is being breastfed) has previously received durlobactam.

  18. Patient (or patient's mother, if the patient is being breastfed) has received sulbactam and/or sulbactam-containing regimens (eg, Unasyn) within 72 hours of first dose of the study drug.

  19. Patient (or patient's mother, if the patient is being breastfed) has received amphotericin B within 7 days of first dose of the study drug.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1

Pediatric patients 12 years to <18 years of age

Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur
实验性的:Cohort 2

Pediatric patients 6 years to <12 years of age

Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur
实验性的:Cohort 3

Pediatric patients 1 year to <6 years of age

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur
实验性的:Cohort 4

Pediatric patients 3 months to <1 year of age

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur
实验性的:Cohort 5 Subgroup 1

Aged 2 months to <3 months, term and preterm (gestational age >28 weeks)

Term infants will receive 25mg/kg SUL and 25mg/kg DUR

Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur

20mg/kg SUL and 20mg/kg DUR

其他名称:
  • Sul-dur
实验性的:Cohort 5 Subgroup 2

Aged birth to <2 months, term and preterm (gestational age >28 weeks and post-natal age >7 days)

Term infants will receive 25mg/kg SUL and 25mg/kg DUR

Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

25mg/kg SUL and 25mg/kg DUR

其他名称:
  • Sul-dur

20mg/kg SUL and 20mg/kg DUR

其他名称:
  • Sul-dur

研究衡量的是什么?

主要结果指标

结果测量
大体时间
评估Sulbactam和Durlobactam的最大浓度(CMAX)的药代动力学(PK)参数
大体时间:第1天和第3天
第1天和第3天
评估血浆浓度时间曲线下面积的PK参数,从0到24小时(AUC 0-24)和Durlobactam
大体时间:第1天和第3天
第1天和第3天

次要结果测量

结果测量
措施说明
大体时间
严重 TEAE 的发生率
大体时间:28天
28天
导致研究药物停用的茶的百分比
大体时间:28天
28天
相关茶的发病率
大体时间:28天
28天
通过综合代谢面板(CMP)测量的肝功能的基线值的变化
大体时间:基线和第28天
基线和第28天
与CMP测量的肾功能的基线值的变化
大体时间:基线和第28天
基线和第28天
从血红蛋白的基线值变化
大体时间:基线和第28天
基线和第28天
从白细胞计数的基线价值变化
大体时间:基线和第28天
基线和第28天
从血小板的基线价值变化
大体时间:基线和第28天
基线和第28天
从舒张压的基线价值变化
大体时间:基线和第28天
基线和第28天
从收缩压的基线值变化
大体时间:基线和第28天
基线和第28天
从心率的基线值变化
大体时间:基线和第28天
基线和第28天
从呼吸速率的基线价值变化
大体时间:基线到第28天
基线到第28天
从温度的基线值变化
大体时间:基线和第28天
基线和第28天
Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs)
大体时间:28 days

Defined as any adverse event occurring after exposure to the study drug or any AE that worsens in intensity or frequency

28 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月30日

初级完成 (估计的)

2028年5月5日

研究完成 (估计的)

2028年5月20日

研究注册日期

首次提交

2025年1月16日

首先提交符合 QC 标准的

2025年1月22日

首次发布 (实际的)

2025年1月30日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享时间框架

Data requests may be submitted starting 6 months after primary article publication and the data will be made accessible for up to 24 months; extensions may be considered on a case-by-case basis. Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review

IPD 共享访问标准

Subject to certain criteria, conditions, and exceptions and upon completion of the review and approval of the Research Proposal and Statistical Analysis Plan, Qualified Researchers engaging in independent scientific research can be provided de-identified IPD following the execution of a Data Sharing Agreement

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅